News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
BioVex IPO Set At 3.4M Shares
September 1, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cancer treatment developer BioVex Group Inc. plans to offer 3.4 million common shares via its initial public offering, according to an amended IPO filing with regulators.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
July 27, 2026
·
2 min read
·
Tristan Manalac
IPO
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
July 24, 2026
·
3 min read
·
Tristan Manalac
Psychedelics
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
July 24, 2026
·
3 min read
·
Gabrielle Masson
Manufacturing
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
July 22, 2026
·
2 min read
·
Nick Paul Taylor
